Related Experiment Video
Updated: Feb 17, 2026

06:46
Automated, Long-term Behavioral Assay for Cognitive Functions in Multiple Genetic Models of Alzheimer's Disease, Using IntelliCage
Published on: August 4, 2018
12.8K
Music models aberrant rule decoding and reward valuation in dementia
Camilla N Clark1, Hannah L Golden1, Oliver McCallion2
1Dementia Research Centre, UCL Institute of Neurology, University College London, London, UK.
Social Cognitive and Affective Neuroscience
|November 30, 2017
Summary
Music tasks reveal distinct cognitive deficits in dementia. Frontotemporal dementia (FTD) patients struggle with rule and reward processing, while Alzheimer's disease (AD) patients show impaired rule decoding.
Area of Science:
- Neuroscience
- Cognitive Psychology
- Neurology
Background:
- Socio-emotional behavior abnormalities in major dementias are linked to aberrant rule and reward processing.
- These underlying cognitive processes are not well understood in dementia subtypes.
Purpose of the Study:
- To investigate rule decoding and reward valuation using music in patients with frontotemporal dementia (FTD) syndromes and Alzheimer's disease (AD).
- To compare cognitive performance in these patient groups with healthy age-matched individuals.
Main Methods:
- Participants classified short melodies as 'finished' or 'unfinished' (rule processing) and rated their pleasantness (reward valuation).
- Analyses included adjustments for pitch and executive function, with neuroanatomical correlates assessed via voxel-based morphometry.
Main Results:
- Behavioral variant FTD patients exhibited deficits in both rule decoding and reward valuation.
- Semantic dementia patients showed impaired reward valuation but intact rule decoding.
- Alzheimer's disease patients demonstrated impaired rule decoding but intact reward valuation.
- Progressive non-fluent aphasia patients performed similarly to controls.
Conclusions:
- Musical rule and reward processing offer insights into cognitive and neuroanatomical mechanisms underlying socio-emotional dysfunction in dementia.
- Specific impairments in rule decoding and reward valuation correlate with distinct dementia subtypes and brain regions like orbitofrontal cortex.
Related Concept Videos
Dementia
584
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
584
Neural Regulation
43.5K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
43.5K
Alzheimer's Disease: Overview
1.8K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.8K
Alzheimer's Disease: Treatment
1.0K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.0K

